Rezubio Announces FDA and NMPA IND Clearances and First Cohort Dosing of RZ-520, a Novel Inhaled Therapy for Chronic Respiratory Diseases
核心洞察
Rezubio (搜索) has completed dosing of the first cohort in its Phase 1 clinical trial of RZ-520 (搜索) following dual IND clearances from the US FDA and Chinese NMPA.
RZ-520 (搜索) is a novel inhaled therapeutic candidate for chronic respiratory diseases (搜索), designed to provide sustained local lung exposure while limiting systemic distribution.
The Phase 1 trial evaluates the safety, tolerability, pharmacokinetics, and pharmacodynamics of RZ-520 (搜索) in healthy volunteers.
Rezubio (搜索) today announced that it has successfully completed dosing of the first cohort in its Phase 1 clinical trial following clearances from the US FDA and Chinese NMPA. The trial evaluates the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of RZ-520 (搜索) in healthy volunteers.
RZ-520 (搜索) is the second clinical-stage asset developed using Rezubio (搜索)'s proprietary Membrane-Anchored Drug Design (MADD) platform. It is designed to deliver a best-in-class profile against a validated drug target. In preclinical studies, inhaled RZ-520 demonstrated robust therapeutic efficacy across multiple disease models, with superior safety and negligible systemic drug exposure.
"The dual IND clearances from the FDA and NMPA and first cohort dosing of RZ-520 (搜索) mark a pivotal milestone for both this program and our MADD platform," said Yusheng Xiong, CEO of Rezubio (搜索). "Advancing our second MADD-derived drug candidate into clinical development further validates the power of our platform to design tissue-targeted therapies that address a broad spectrum of challenging diseases. We look forward to advancing these clinical studies and evaluating RZ-520's potential to deliver a transformative and highly differentiated treatment option for patients living with chronic respiratory diseases (搜索)."
About RZ-520
RZ-520 (搜索) is a novel inhaled therapeutic drug candidate for the treatment of chronic respiratory diseases (搜索). The molecule is designed to provide sustained local drug exposure in the lung while limiting systemic distribution, with the goal of improving efficacy, safety, and dosing convenience.
About the MADD Platform
Membrane-Anchored Drug Design (MADD) is Rezubio (搜索)'s proprietary platform for engineering tissue-targeted therapeutics with prolonged local residence and optimized pharmacokinetic properties. The platform enables the development of clinically differentiated therapies targeting various cell surface proteins in both the respiratory tract and gastrointestinal (GI) tract.